General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Tykerb & Letrozole (lapatinib)
Status:
Negotiations were not pursued
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer
Last updated August 9, 2013
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Non-Squamous Non-Small Cell Lung Cancer
Last updated August 8, 2013
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Acute Coronary Syndrome
Last updated August 7, 2013
Seebri (glycopyrronium bromide)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Chronic Obstructive Pulmonary Disease (COPD)
Last updated July 29, 2013
Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
HIV-1 Infection
Last updated July 11, 2013
Status:
Concluded with an LOI
Manufacturer:
Eisai Limited
Indication:
Metastatic Breast Cancer
Last updated July 2, 2013
Status:
Concluded without agreement
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated June 13, 2013
Status:
Concluded with an LOI
Manufacturer:
Biogen Canada Inc.
Indication:
Multiple Sclerosis, Relapsing-Remitting
Last updated December 1, 2013
Treanda (bendamustine hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
Lundbeck Canada Inc.
Indication:
Non-Hodgkin's Lymphoma
Last updated April 25, 2013
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Chronic Obstructive Pulmonary Disease (COPD)
Last updated April 12, 2013